Evaluation of antihypertensive efficacy of lisinopril compared to metoprolol in moderate to severe hypertension. 1987

P K Zachariah, and G Bonnet, and S G Chrysant, and G DeBacker, and R Goldstein, and J Herrera, and A Lindner, and B J Materson, and M H Maxwell, and F G McMahon

A double-blind controlled, randomized, parallel, multicenter 12-week study was conducted to compare the antihypertensive efficacy of lisinopril with that of metoprolol in treatment of moderate to severe hypertension. Initially, 118 patients were recruited on lisinopril and 61 on metoprolol; and for the purpose of efficacy analysis at week 8, 115 patients on lisinopril and 60 on metoprolol were included. The doses of lisinopril or metoprolol were 40-80 mg/day and 100-200 mg/day, respectively. At week 4, the pretreatment diastolic blood pressure of 111 mm Hg was decreased to 97 mm Hg (p less than 0.01) with lisinopril: metoprolol decreased the diastolic blood pressure from 110 to 99 mm Hg (p less than 0.01). Similar decreases were noted at week 8; however, the drop in blood pressure with lisinopril was not significantly different from that with metoprolol. Systolic blood pressure also demonstrated a decrease of about 18 mm Hg with lisinopril and 12 mm Hg with metoprolol (p less than 0.01). This larger decrease in systolic blood pressure with lisinopril was statistically significant at week 4 (p less than 0.05). These decreases in systolic blood pressures were maintained at week 8, again with statistical significance (p less than 0.01). Of the 118 lisinopril-treated patients, four were discontinued from lisinopril therapy because of headache, dizziness, rash, flushing, or lymphadenopathy. Four patients out of 61 (9.8%) were discontinued from metoprolol therapy because of fatigue, somnolence, asthenia, weight gain, flatulence, tremor, or bronchospasm. In conclusion, lisinopril 40-80 mg once daily is as effective as metoprolol 100-200 mg once daily in reducing diastolic blood pressure in patients with moderate to severe hypertension.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D008790 Metoprolol A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS. Beloc-Duriles,Betaloc,Betaloc-Astra,Betalok,CGP-2175,H 93-26,Lopressor,Metoprolol CR-XL,Metoprolol Succinate,Metoprolol Tartrate,Seloken,Spesicor,Spesikor,Toprol,Toprol-XL,Beloc Duriles,Betaloc Astra,CGP 2175,CGP2175,H 93 26,H 9326,Metoprolol CR XL,Toprol XL
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004656 Enalapril An angiotensin-converting enzyme inhibitor that is used to treat HYPERTENSION and HEART FAILURE. Enalapril Maleate,MK-421,MK421,Renitec,Renitek,MK 421,Maleate, Enalapril
D005260 Female Females

Related Publications

P K Zachariah, and G Bonnet, and S G Chrysant, and G DeBacker, and R Goldstein, and J Herrera, and A Lindner, and B J Materson, and M H Maxwell, and F G McMahon
January 1987, Journal of cardiovascular pharmacology,
P K Zachariah, and G Bonnet, and S G Chrysant, and G DeBacker, and R Goldstein, and J Herrera, and A Lindner, and B J Materson, and M H Maxwell, and F G McMahon
June 1991, Journal of human hypertension,
P K Zachariah, and G Bonnet, and S G Chrysant, and G DeBacker, and R Goldstein, and J Herrera, and A Lindner, and B J Materson, and M H Maxwell, and F G McMahon
June 1992, Angiology,
P K Zachariah, and G Bonnet, and S G Chrysant, and G DeBacker, and R Goldstein, and J Herrera, and A Lindner, and B J Materson, and M H Maxwell, and F G McMahon
January 1994, Therapie,
P K Zachariah, and G Bonnet, and S G Chrysant, and G DeBacker, and R Goldstein, and J Herrera, and A Lindner, and B J Materson, and M H Maxwell, and F G McMahon
October 2007, Blood pressure. Supplement,
P K Zachariah, and G Bonnet, and S G Chrysant, and G DeBacker, and R Goldstein, and J Herrera, and A Lindner, and B J Materson, and M H Maxwell, and F G McMahon
January 1989, Journal of cardiovascular pharmacology,
P K Zachariah, and G Bonnet, and S G Chrysant, and G DeBacker, and R Goldstein, and J Herrera, and A Lindner, and B J Materson, and M H Maxwell, and F G McMahon
October 2007, Blood pressure. Supplement,
P K Zachariah, and G Bonnet, and S G Chrysant, and G DeBacker, and R Goldstein, and J Herrera, and A Lindner, and B J Materson, and M H Maxwell, and F G McMahon
June 2003, Journal of human hypertension,
P K Zachariah, and G Bonnet, and S G Chrysant, and G DeBacker, and R Goldstein, and J Herrera, and A Lindner, and B J Materson, and M H Maxwell, and F G McMahon
June 1989, Journal of human hypertension,
P K Zachariah, and G Bonnet, and S G Chrysant, and G DeBacker, and R Goldstein, and J Herrera, and A Lindner, and B J Materson, and M H Maxwell, and F G McMahon
January 1999, Terapevticheskii arkhiv,
Copied contents to your clipboard!